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for bleeding remain important and include use of amino-
caproic acid and HLA matched platelets, prevention of hy-
pertension while thrombocytopenic, pre-transplant testing
for platelet reactive antibodies so HLA matched platelets
may be obtained sooner, and choice of transplant condi-
tioning regimen.281
Neck Tenderness As an Initial Presentation of
Disseminated Aspergillosis; FNA Is an Option or a Must?
Sherif Badawy. Division of Pediatric Hemtology, Oncology and
Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital
of Chicago, Northwestern University Feinberg School of
Medicine, Chicago, IL
Introduction: Asperillus thyroiditis (AT) has been consid-
ered for long time a postmortem diagnosis in immunocom-
promised patients. Disseminated disease is seen in the
majority of patients. Diagnosis of AT during life needs high
index of suspicion.
Objective: We describe an adolescent HSCT recipient with
disseminated aspergillus infection who presented initially
with painful neck swelling and found to have AT.
Case Report: History: A 15 years-old male with history of
Acute Myeloid Leukemia and MUD HSCT who presented to
our institution with painful neck swelling, sore throat, red/
brown sputum and worsening respiratory distress for 2 days.
Mom had of Hashimoto’s thyroiditis. Physical Exam: His had
initial hypotension, tachycardia, tachypnea and ﬁne hand
tremors. He had a neck swelling that was moving up and
down on swallowing with tenderness but no nodules on
palpation. Laboratory: His evaluation showed thrombocyto-
penia, normal WBC counts with neutrophil predominance,
hypokalemia, transaminitis, direct hyperbilirubinemia,
elevated Free T4 and very low TSH. Fine needle aspirate
(FNA) of the thyroid and the sputum showed yeast on KOH.
Imaging: Thyroid US with diffuse heterogeneous enlarge-
ment. CT Chest showed moderate to large areas of pulmo-
nary consolidation bilaterally, with areas of cavitation.
Clinical course: He was started on broad-spectrum antibi-
otics and antifungals. His respiratory and mental status got
worse one day after admission needing transfer of care to the
Pediatric ICU. His FNA of the thyroid grew Aspergillus
Fumigatus. MRI brain showed numerous rounded lesions
consistent with disseminated fungal disease, most likely
Aspergillus. Family chose to continue with palliative care
only with DNR/DNI having his disseminated disease and
critical condition.Discussion: Our patient had evidence of disseminated
invasive aspergillosis involving thyroid, lungs and brain.
Initially he had presumed infectious thyroiditis based on his
clinical examination and laboratory values that were
conﬁrmed to be AT. Thyroid-related symptomatology can be
occasionally seen on presentation. Although viral sub-acute
and bacterial thyroiditis is more common than fungal one,
but in immunocompromised patients AT has to be consid-
ered early on. Thyroid US guided FNA cytology and culture is
considered to be a well-tolerated procedure that frequently
utilized to diagnose AT successfully. Any delay in the man-
agement may signiﬁcantly affect the outcomes where thy-
roid FNA can play a critical role in the early diagnosis of AT.
Conclusion: The diagnosis of Aspergillus Thyroiditis requires
a high index of suspicion and it can be the initial presentation
of disseminated invasive aspergillosis. Further studies are
needed to evaluate the beneﬁts of combined antifungals and
address the management of thyroid hormone dysregulation.282
Low Dose Deﬁbrotide for Management of Hepatic Veno-
Occlusive Disease
Bhausaheb Bagal, Aliya Choughale, Navin Navin Khattry. Tata
Memorial Centre, BMT Unit, ACTREC, Navi Mumbai, India
Background and objective: Hepatic veno-occlusive disease
(VOD) is recognized as one of the common and serious
regimen-related toxicity seen after hematopoietic stem cell
transplantation (HSCT). VOD develops in 10% to 60% of pa-
tients after HSCT, and ranges in severity frommild to a severe
syndrome associated with multiorgan failure and death.
Deﬁbrotide (DF) is the only drug found to be effective in the
management of VOD. A randomised study showed that 25
mg/kg/d was equally effective with lesser toxicity compared
to 40mg/kg/d. DF is prohibitively expensive and availability is
scarce in our country.
Methods: Two hundred and ninety nine patients (166
autologous and 133 allogeneic; 210 male and 89 female) who
underwent HSCT between November 2007 and June 2013
were included in this study. All patients received ursodeox-
ycolic acid as prophylaxis. The diagnosis and severity of VOD
was deﬁned according to Seattle criterion. Risk of develop-
ment of severe VOD was estimated by Bearman model.
Patients who developed VOD were initially treated with
frusemide and analgesia. Patients not responding to above
measures in 36-48 hours were given DF.
Results: Seven patients (2.3%) were diagnosed with VOD at a
median of days +14 post transplant (range 11 to 16 days). All
7 patients were classiﬁed as having moderate VOD. All
Patient and disease characteristics
Case No 1 2 3 4 5 6 7
Age 21 45 4 42 46 12 29
Diagnosis CML-CP AML JMML AML CML -BC AML SAA
Conditioning
regimen
FLU-MEL Flu-Busulfan Flu-Bu-Mel FLA+Ara-C+Ida+Mel Flu-Mel Flu-Mel-Ara-c-ATG Flu-CY
Risk factor High Ferritin Haplo-HSCT High Ferritin,
MUD HSCT
High Ferritin
VOD on day 11 11 12 14 14 14 16
Maximal Bilirubin 3.8 5 1.2 1.4 3.2 1.34 3.1
Weight gain (%) 5 22 10 7.5 5 3 13
Bearman score 10 10 20 16 12 11 16
DF Dose mg/kg/d 5 7 7 5 10 10 10
Duration 6 12 10 6 8 8 12
Resolution by D+17 D+28 D+21 D+20 D+22 D+10 D+24
Organ
dysfunctioon
hepatic
encephalopathy
Oxygen
desaturation
renal failure,
hepatic encephalopathy,
Oxygen desaturation
Oxygen
desaturation
renal dysfunction,
hepatic encephalopathy,
oxygen desaturation
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mg/kg/d in two divided doses for median of 8 days (range 6
to12 days). Six patients received intravenous DF while 1
patient received oral DF. All patients had complete resolution
of VOD by day +22 post transplant (range day + 17 to day
+28). No dose response relationship was observed between
DF dose and time to resolution of VOD. None developed any
side effects of DF.
Conclusion: A lower dose of DF is effective and safe in treat-
ment of moderate VOD. This is especially relevant in a limited
resource setting, however needs prospective evaluation.
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Follow-up of Vaccination Status in Adults after Allogeneic
Hematopoietic Stem Cell Transplantation
Tiene Bauters 1, Lise Dinh 1, Johan De Munter 2,
Marijke Quaghebeur 2, Dominiek Mazure 2, Lucien Noens 2,
Tessa Kerre 2. 1 Pharmacy, Ghent University Hospital, Ghent,
Belgium; 2Hematology and Stem Cell Transplantation, Ghent
University Hospital, Ghent, Belgium
Background: Following hematopoietic stem cell trans-
plantation (HSCT), the probability that acquired protective
immunity is lost over time is signiﬁcant. Therefore, a sys-
tematic reimmunization is important to re-establish appro-
priate immunity and to decrease the risk of vaccine
preventable infectious diseases with their related morbidity
and mortality. The aim of this study is to investigate whether
the recommendations for vaccination were followed in our
hospital and to which extent of conformity they were used.
Methodology: A 2-year retrospective survey, including adult
allogeneic HSCT patients, (transplanted) at the Ghent Uni-
versity Hospital, Belgium, who were at least 3 months post
transplant. Administration of the ﬁrst dose of conjugated
polysaccharide vaccine against Pneumococci was studied.
Results: Data on vaccination schedules of 50 allogeneic
transplantations were collected. Of these, 34 patients (68,0%)
were eligible for recommended vaccinations. Patients were
vaccinated on-schedule (i.e. time-frame between HSCT and
vaccination as recommended in the hospital guideline) in
76,5% (26/34). Postponed vaccination with a medical indi-
cationwas observed in 8,8% (3/34) of patients. Of them, 66,7%
(2/3) were postponed because of infection and 33,3% (1/3)
because of signiﬁcant thrombocytopenia.
Postponed vaccination without a medical excuse was
observed in a minority of the patients, i.e. 11,8% (4/34), with
either ‘no medical reason’ in 75,0% (3/4) or nonadherence in
25,0% of patients (1/4). Postponed vaccination with initialmedical indication but then followed by non-medical reason
was observed in 2,9% (1/34) of patients. Vaccination data
were not available for 32,0% (16/50) of patients. The reasons
were death before start of vaccination in 75,0% (12/16), graft
failure in 12,5% (2/16) and lack of information in 12,5% (2/16)
of patients.
Conclusion: The results emphasize the need for close follow-
up of post-transplant patients in our hospital. This is
conﬁrmed by satisfactory concordance between the hospital
recommendation and vaccination of HSCT patients. Health-
care providers play a crucial role by effectively and appro-
priately following the vaccination schedules. Moreover,
literature data demonstrate that actively involving the pa-
tient in the follow-up (e.g. providing them with their vacci-
nation schedule) results in improved follow-up. The role of a
personalized electronic alert systemwill be explored in near
future. In addition, the appropriate follow-up of out-patient
vaccination, 1 year after HSCT, will be studied.
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Tolerability of Foscarnet As a Continuous Infusion for
Treatment of Herpesvirus Infections
Janice (Wes) M. Brown 1, Abraham Chang 2, Fu-ying Lee-Lam 2,
Susanna K. Tan 3, Sumana Shashidhar 4. 1 Stanford Univ Med
Ctr, Stanford, CA; 2 Pharmacy, Stanford Hospital and Clinics,
Stanford, CA; 3Medicine/Infectious Diseases, Stanford
University, Stanford, CA; 4Medicine/Blood and Marrow
Transplantation, Stanford University, Stanford, CA
Foscarnet (FOS) remains the primary antiviral option in the
setting of intolerance of and/or resistance to ganciclovir (GCV)
and other inhibitors of viral kinase. However, FOS-associated
nephrotoxicity often limits it utility. Because this nephrotox-
icity can be attenuated by substantially increasing the infusion
time and ensuring adequate hydration, we report a successful
approach to the administration of FOS as a continuous infu-
sion (CI) in both the inpatient and outpatient settings. The
decision regarding administering FOS as a CI was solely at the
discretion of the treating team with most common reasons
cited as attenuation of nephrotoxicity, management of ﬂuid
balance, and facilitation of outpatient care.
Results: Data regarding both groups is summarized in Table
1. Throughout administration, total daily dose was adjusted
per recommendations based on creatinine clearance and
adjusted ideal body weight with an additional liter of
hydration daily. Median duration of treatment was 23 days
(4-123d). 22 of the 25 treatment courses (23 patients)
resulted in successful resolution of the disease process;
